Tty Biopharm Company Limited · TPEX:4105
Tty Biopharm — 1H 2024 Earnings Presentation
12 slides from Tty Biopharm's earnings presentation, Aug 28, 2024
Slide 1: TTY Biopharm Operational Results Report
TTY Biopharm 4105 Operational Results Report 2024.08.28
Slide 2: Disclaimer
Disclaimer This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, TTY Biopharm cautions that this foregoing list of factors is not ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’,
Slide 3: Operational Results Report 1H/2024 Agenda
Operational Results Report 1H/2024 Operational Highlights 1H/2024 Financial Performance 01 Q2/2024 Operational Highlights 2024 Outlook 2
Slide 4: Strong Revenue with Overseas Market Expansion
Strong Revenue with Overseas Market Expansion Operational Results Report Revenue Overview √ YoY Consolidated Revenue √ Consolidated Operating √ EPS remained app. the same 1H/2024 Operational +9% (2.65 billion) Gross Margin 60% as same period last year 2.2 Highlights Market Development Highlights • R
Slide 5: Three Arrows of Operation with Outstanding Results
Three Arrows of Operation with Outstanding Results Operational Results Report Export the Difficulty Generic Drugs • Received milestone from overseas market of long-lasting microsphere drug, OT2015. 1H/2024 Operational • Received milestone from European market of liposome products, Amphotericin B, Li
Slide 6: Product Pipeline: Self-develop, License-in, Cooperation
Product Pipeline: Self-develop, License-in, Cooperation Operational Results Report • Alliance with international partners to strengthen the advantage of the product portfolio • Joint-develop specialty of generic drugs with international partners and expand overseas markets 1H/2024 Oncology 2024 2025
Slide 7: Deploy Globally and Expand Overseas Market
Deploy Globally and Expand Overseas Market Operational Results Report • License-in/ collaboration/ sales 130 drugs in 18 countries globally. • The export market will continue to grow and expand steadily, focusing on the development of the US and other major markets. 1H/2024 • Deepen cooperation with
Slide 8: 1H/2024 Financial Performance
Operational Results Report 1H/2024 Operational Highlights 1H/2024 Financial Performance 02 1H/2024 Financial Performance 2024 Outlook 7
Slide 9: 1H/2024 Financial Performance
1H/2024 Financial Performance Operational Results Report Income Statement （Unit: NT Thousand, 1H/2024 1H/2023 YoY % 1H/2024 Financial Performance 1H/2024 except EPS） Operational • YoY consolidated revenue +9% due to the royalty Net Sales 2,648,256 2,427,895 +9% Highlights income, high growth of over
Slide 10: 1H/2024 Steady Revenue Growth
1H/2024 Steady Revenue Growth Operational Results Report 1H/2024 Revenue Breakdown 1H/2024 Revenue Growth 1H/2024 Operational Highlights Product Category % Revenue (NT Mn) 49% 2,750 $24 $120 Oncology -$7 -$19 $2,648 1H/2024 2,650 -$36 Financial Intensive Care $138 Performance 2,550 Healthcare 23% 2,
Slide 11: 2024 Outlook
Operational Results Report 1H/2024 Operational Highlights 1H/2024 Financial Performance 03 2024 Outlook 2024 Outlook 10
Slide 12: Core Strategy and the Three Arrows are Implemented
Core Strategy and the Three Arrows are Implemented Operational Results Report 1 Strengthen Global Deployment 1H/2024 Explore potential products and expand international market through Operational authorization, distribution, strategic cooperation and M&A. Highlights License-in the International New